Is Ketamine Infusion an Effective Treatment for Post-Traumatic Stress Disorder? A Meta-Analysis

doi:10.21203/rs.3.rs-3559310/v1

Post-traumatic stress disorder (PTSD) affects ~ 6% of adolescents and adults in the US. Increased N-methyl-D-aspartate (NMDA) receptor activation leads to heightened intrusive memories and is associated with an increased risk of developing PTSD. Ketamine is an NMDA antagonist with ultra-rapid therapeutic action for treatment-resistant depression and suicide. In this meta-analysis, we assessed the effect of subanesthetic ketamine infusion on PTSD severity. Six databases were investigated according to PRISMA guidelines with quality assessments according to the NIH Quality Assessment tool. Eligible criteria included: 1) Randomized Control Trial (RCT) or cohort study 2) Used a single or multiple ketamine infusion(s) 3) Studies using another treatment for PTSD to which (2) is added 4) PTSD symptoms are measured at pre-infusion baseline and up to at least 40 minutes after infusion using a valid PTSD symptom measurement scale 5) Study included ≥ 5 patients. The primary outcome was the first measured value of PTSD symptoms after treatment completion. Meta-analysis using a random effects model was performed on pre-to-post changes in PTSD severity within ketamine treated patients and to compare ketamine to control outcomes. The search retrieved 526 articles. Nine articles met inclusion criteria: 5 RCTs and 4 cohort studies. Meta-analysis revealed that ketamine infusion reduced PTSD symptom severity (pre-post ketamine: standardized mean difference pre-to-post: 3.07, 95% confidence interval 1.54–4.60, P < 0.01). These results support ketamine infusions as an effective treatment modality for PTSD symptoms. Ketamine-assisted psychotherapy is shown to enhance ketamine effect and aid in prolonging remission. Further research is needed to provide effective and long-lasting PTSD treatment.

Post-traumatic stress disorder

Ketamine

Ketamine-assisted psychotherapy

N-methyl-D-aspartate receptor

Meta-analysis

Post-traumatic stress disorder (PTSD) is a chronic psychiatric disorder which is characterized by persistent vivid recall of past severe traumatic events [1]. It affects an estimated 6.0% of adults and 5.0% of adolescents in the United States [1, 2]. Because PTSD by definition is related to an experienced traumatic event, populations with significant exposure to traumatic events such as veterans and the victims of sexual assault/intimate partner violence have a markedly increased risk of developing PTSD [3, 4]. PTSD is associated with substantial comorbidities such as treatment resistant depression, substance abuse, suicidality, loss of quality of life and considerable societal burden through loss of productivity [5]. The limited number of pharmacological agents currently approved for treatment of PTSD lack significant efficacy, and medications as well as psychotherapy have long latency for their onset of therapeutic actions. Two selective serotonin reuptake inhibitors (SSRIs), sertraline and paroxetine, are approved by the United States Food and Drug Administration (FDA) for treatment of PTSD [6, 7]. Unfortunately, less than 60% of patients with PTSD respond to SSRIs and only 20–30% of patients achieve full remission of symptoms [6, 7]. Pharmacological response is further diminished in patients with severe PTSD, such as veterans [8]. Due to the low efficacy of SSRIs, serotonin–norepinephrine reuptake inhibitors and atypical antipsychotic drugs are commonly used off-label as first line treatments [6, 9].

In light of the limited treatment effects of existing pharmacotherapy for PTSD, trauma- and trauma non-focused psychotherapies are the first line treatment modalities. Trauma focused approaches include cognitive behavioral therapies (CBTs) such as cognitive processing therapy, prolonged exposure therapy, eye movement desensitization and reprocessing and more recently, mindfulness-based cognitive therapy such as TIMBER (trauma interventions using mindfulness-based extinction and reconsolidation of trauma memories) [10, 11]. The trauma non-focused approaches are stress inoculation training and CBT as usual. However, with high dropout and non-response rates there is limited short lived efficacy for therapy as a sustained treatment [12].

While the active pursuit by the scientific community for a rapid and effective medication for PTSD is still ongoing [13], ketamine, a glutamate (N-methyl-D-aspartate type/NMDA) receptor antagonist and well known since 1960s for its anesthetic use, has recently proven in a pivotal trial to be efficacious in treatment resistant depression that led to its 2019 approval by the US FDA in its aerosol formulation for the intranasal route of usage [14–16]. Data is emerging for Ketamine’s ultra-rapid therapeutic actions (in 40-minutes) in chronic PTSD as well [15, 17]. In PTSD, increased NMDA receptor activation leads to heightened intrusive memories and is associated with an overall increased risk of developing PTSD [18–20]. Additionally, work by one of the authors and colleagues suggest that increase in the serum concentration of D-serine, an NMDA receptor co-agonist, can serve as a biological marker of severity and clinical response to ketamine and mindfulness therapy (TIMBER) in chronic PTSD and co-morbid treatment resistant depression [11]. Thus, extending its therapeutic effects on treatment resistant depression, ketamine has garnered attention as a potential treatment for PTSD as well. This development is important because ketamine’s therapeutic effects are ultra-rapid and in preliminary studies it has shown therapeutic effects in suicidality and substance abuse (opioids, alcohol, cocaine) as well [21].

Previous narrative reviews have discussed ketamine’s potentially unique role for the treatment of PTSD based on emerging evidence from both animal and human models [18, 22]. Clinical studies on the clinical efficacy of ketamine to treat PTSD are rapidly emerging and there is a need to synthesize the current state of evidence for clinical use. We conducted a systematic literature review and meta-analysis assessing the efficacy of subanesthetic intravenous ketamine (0.5–1 mg/kg) to reduce PTSD severity.

The systematic review was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines [23]. This study was registered with the International Prospective Register of Systematic Reviews (PROSPERO, Registration number: CRD42020184237) [24].

Search Criteria:

PubMed, Embase, Cochrane, Clincialtrials.gov, Web of Science, and Google Scholar databases were searched on 4/2020. No limits on date range, place of publication, or language were used. The search terms for two databases which obtained the greatest number of abstracts are presented in Table 1.

Table 1

Search Terms
PubMed	(ketamine OR ketamin* OR ketalar OR calipsol OR ketanest OR ketaset OR calypsol OR kalipsol OR "ci 581" OR “S-ketamine” OR “S ketamine” OR “(S)-ketamine” OR “S(+)-ketamine” OR esketamine OR “R-ketamine” OR “R ketamine” OR "R,S ketamine" OR “(R)-ketamine” or “(R)-(−)-ketamine” OR “R(+)-ketamine” OR arketamine) AND (posttraumatic stress disorder OR "post-traumatic stress disorder" OR ptsd).
Embase	('posttraumatic stress disorder'/exp OR 'posttraumatic stress disorder' OR (posttraumatic AND ('stress'/exp OR stress) AND ('disorder'/exp OR disorder)) OR 'post-traumatic stress disorder'/exp OR 'post-traumatic stress disorder' OR 'ptsd'/exp OR ptsd) AND ('ketamine'/exp OR ketamine OR ketamin* OR 'ketalar'/exp OR ketalar OR 'calipsol'/exp OR calipsol OR 'ketanest'/exp OR ketanest OR 'ketaset'/exp OR ketaset OR 'calypsol'/exp OR calypsol OR 'kalipsol'/exp OR kalipsol OR 'ci 581'/exp OR 'ci 581' OR 's-ketamine'/exp OR 's-ketamine' OR 's ketamine'/exp OR 's ketamine' OR '(s)-ketamine' OR 's(+)-ketamine'/exp OR 's(+)-ketamine' OR 'esketamine'/exp OR esketamine OR 'r-ketamine' OR 'r ketamine' OR 'r,s ketamine' OR '(r)-ketamine' OR '(r)-(−)-ketamine' OR 'r(+)-ketamine' OR arketamine).

All potential studies from the 6 databases were considered for eligibility and a manual search of relevant studies from the reference section of included studies were further reviewed.

Inclusion criteria:

Studies were eligible for inclusion if: 1) Randomized control trail or cohort study 2) Used a single or multiple ketamine infusion(s) as intervention 3) Studies using another treatment for PTSD, to which (2) is added 4) PTSD symptoms are measured at pre-infusion baseline and up to at least 40 minutes after infusion using a valid PTSD symptom measurement scale 5) Study included 5 or more patients. Pediatric studies were excluded.

Outcome measures:

The primary outcome is PTSD symptom severity measured on a validated measurement scale (e.g., PCL-5, CAPS-5, IES-R) before and after ketamine infusion treatment. Side effects and complications of infusion treatment, including but not limited to hypertension or headaches, were additional outcomes of interest.

Study Selection:

Two groups of reviewers (C.M/N.v.H and H.K/B.P) independently screened for eligible studies by assessing title and abstract. If one reviewer deemed a study potentially relevant for inclusion, the full text was assessed for eligibility. Subsequently, all full texts were assessed for inclusion.

In case of a disagreement, consensus was reached through discussion between the two reviewer groups. If consensus was not reached upon initial discussion a third reviewer (L.M) was consulted as a tiebreaker, which led to agreement in all assessments.

Data Collection:

The following data was extracted 1) Location of study, 2) Year of study, 3) Type of study, 4) Number of subjects enrolled, 5) Demographics, 6) Intervention, 7) Ketamine infusion treatment details, 8) Control arm treatment details (if present), 9) Duration, 10) Type of PTSD outcome measurement, 11) Timing outcome measurement, 12) Descriptive statistics of outcome measure 13) PTSD relapse rate, 14) PTSD scale, 15) Side effects of ketamine infusion treatment.

Quality Assessment:

The refined version of the National Heart, Lung, and Blood Institute quality assessment tool was used to evaluate study quality in the present review [25]. Initial assessments of all studies were made independently by 2 reviewers (N.v.H and C.M). In case of a disagreement in quality assessment, consensus was reached through discussion between the 2 reviewers.

Data Analysis Plan:

Random effects modeling was used for meta-analysis. Standardized mean differences between the ketamine and control groups at baseline and post infusion in each included study are reported. The standardized mean differences were pooled by using Hedges-g, which provides a small number correction. In order to estimate the between-study variance (tau), we used a restricted maximum likelihood procedure. R was used for all analyses (R Foundation for Statistical Computing, Vienna, Austria).

Included Studies

Through 6 databases, 526 unique studies were identified that underwent title/abstract review. After a full text review of 65 studies, nine articles met inclusion criteria. These nine articles included five randomized controlled clinical trials [10, 11, 17, 26, 27] and four cohort studies [28–31], Fig. 1.

All nine included studies were conducted in the US between 2014–2021. All studies investigated and reported the change in PTSD symptom severity post intravenous administration of subanesthetic doses of ketamine [10, 11, 17, 26–31].

Quality Assessment

None of the nine articles were found to be of “poor” quality based on the NIH Quality Assessment tool [25]. Two cohorts [28, 31] and five RCTs [10, 11, 17, 26, 27] were found to be of “good” quality. Two cohorts [28, 29] were found to be of “fair” quality (Table 2–3).

A. Randomized Controlled Clinical Trials:

Demographics:

Across the five RCTs, there were 69 females and 53 males with a mean age of patients ranging from 34 to 56 years (Table 4) [10, 11, 17, 26, 27]. The majority of the patients had a prior history of physical and sexual trauma history (Table 5).

Table 4

Study Characteristic (should be placed on Page 11 line 249)
Study	Year of Publication	Type of Study	Study Population Size (F/M)	Intervention	Concertation	Duration	PTSD Scale	Long term Remission (days)
Albott et al²⁸	2018	Open Label Trial	15 (5/10)	6x IV Ketamine HCL	0.5 mg/kg	40 min infusion M, W, F for 12 days	PCL-5	41
Dadabayev et al²⁷	2020	Randomized Clinical Trial	21 (8/13)	1x IV Ketamine or Ketorolac	0.5 mg/kg Ketamine or 15 mg Ketorolac	40 min infusion	IES-R	N/A
Feder et al¹⁷	2014	Randomized Clinical Trial	41 (19/22)	1x IV Ketamine HCL or Midazolam	0.5 mg/kg Ketamine HCL or 0.045 mg/kg Midazolam	40 min infusion and 2nd infusion given if CAPS 2 score ≥ 50 at 2 weeks	IES-R	N/A
Feder et al²⁶	2021	Randomized Clinical Trial	30 (23/7)	6x IV Ketamine HCL or Midazolam	0.5 mg/kg Ketamine HCL or 0.045 mg/kg Midazolam	40 min infusions over 14 days (2–3 infusions weekly)	CAPS-5	27.5
Keizer et al²⁹	2020	Case Series	11 (3/8)	1x IV Ketamine and Psychotherapy	1st infusion 2 µg/kg/min Ketamine, increased 1–2 µg/kg/min every 3–4 hours till 11–15 µg/kg/min Ketamine achieved	1 96-hour infusion with 90 min psychotherapy	PCL-5	N/A
Pradhan et al¹⁰	2017	Randomized Clinical Trial	10 (7/3)	1x IV Ketamine or Normal Saline and TIMBER Psychotherapy	0.5 mg/kg Ketamine or Normal Saline infusion and 12 sessions of TIMBER	40 min infusion and 45 min TIMBER	CAPS-5	33 ± 22.98
Pradhan et al¹¹	2018	Randomized Clinical Trial	20 (12/8)	1x IV Ketamine or Normal Saline and TIMBER Psychotherapy	0.5 mg/kg Ketamine or Normal Saline infusion and 12 sessions of TIMBER	40 min infusion and 45 min TIMBER	CAPS-5	34.44 ± 19.12
Ross et al³⁰	2019	Observational Case Series	30 (n/a)	6x IV Ketamine HCL	1st infusion: 1 mg/kg ketamine of BW* max of 60 mg and future infusions: adjusted to achieve PTR** from 60–300 mg Ketamine	1 hour infusion for 2–3 weeks	PCL-5	N/A
Shiroma et al³¹	2020	Open Label Trial	9 (3/6)	3x IV Ketamine and Prolonged Exposure (PE) Psychotherapy	0.5 mg/kg Ketamine and 10 sessions of Prolonged Exposure Psychotherapy	40 min infusions, 24 hours prior to 3 weekly PE followed by 7 additional PE sessions	CAPS-5	N/A
Body Weight *PTR: Psychotropic Therapeutic Response (experiences optimum transpersonal and transformative experience)

*Table 4 (attached in the end of the document due to its landscape orientation)*

Table 5

Trauma Type and Comorbidities
Study	Year	Study Population Size (F/M)		Emotional	Combat	Sexual	Accident/Fire	Witnessed Trauma	Depression
Albott et al²⁸	2018	15 (5/10)	6.7%	N/A	53.3%	33.3%	6.7%	N/A	100%
Dadabayev et al²⁷	2020	21 (8/13)	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Feder et al¹⁷	2014	41 (19/22)	26.82%	N/A	4.87%	21.95%	9.75%	26.82%	N/A
Feder et al²⁶	2021	30 (23/7)	26.66%	N/A	6.66%	43.33%	0%	23.33%	70%
Keizer et al²⁹	2020	11 (3/8)	18.18%	N/A	90.90%	18.18%	N/A	N/A	N/A
Pradhan et al¹⁰	2017	10 (7/3)	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Pradhan et al¹¹	2018	20 (12/8)	60%	15%	5%	65%	15%	N/A	N/A
Ross et al³⁰	2019	30 (n/a)	N/A	N/A	100%	N/A	N/A	N/A	N/A
Shiroma et al³¹	2020	9 (3/6)	11.11%	N/A	44.44%	44.44%	N/A	N/A	66.66%

Diagnostic Criteria:

The baseline diagnostic criteria of PTSD were consistent across the five RCTs. All included patients had a current diagnosis of PTSD, most cases persisted for at least 1 year with partial or lack of response to concomitant psychotropic medications and/or CBT trials. Diagnosis of PTSD was assessed with either the DMS – IV [10, 11, 17] or V [26, 27] criteria and a CAPS-5 score of ≥ 30 [26] or ≥ 50 [17]. Feder et al 2014 required patients to be free of psychotropic medications for 2 weeks prior to randomization and for the duration of the study [17]. Pradhan et al 2017 and 2018, Dadabayev et al 2020, and Feder et al following study in 2021 allowed patients to continue stable doses of psychotropic medications prior to randomization and throughout the study with the caveat of allowing patients the opportunity to taper off medication that was ineffective or deemed medically unnecessary prior to randomization [10, 11, 26, 27]. Notable exclusion criteria included unstable medical conditions, active suicidal or homicidal ideation, lifetime history of psychotic or bipolar disorder, current bulimia or anorexia nervosa, alcohol abuse or dependence in the previous 3 months, history of recreational ketamine or phencyclidine use in the past 2 years, and current treatment with a long-acting benzodiazepine or opioid medication [17, 26, 27]. Although use of marijuana or cannabis derivatives was permitted, patients with marijuana use disorder were excluded [26].

Interventions:

The interventions varied for each RCTs and ranged from a single infusion to six ketamine infusions. Two studies combined the novel approach of TIMBER psychotherapy with ketamine pharmacotherapy [10, 11]. For details, please refer to Table 4.

RCT Efficacy Results:

All five RCTs reported a rapid and significant reduction in PTSD severity following ketamine infusions [10, 11, 17, 26, 27].

Feder et al first analysis in 2014 randomly assigned 41 patients who received ketamine or midazolam infusions [17]. All patients were diagnosed with comorbid PTSD and depression. Twenty-nine patients completed the two-infusion protocol, 6 patients who completed one infusion of ketamine, as their CAPS-5 scores were < 50 at 2 weeks, precluding the second infusion, and another 6 patients were withdrawn due to dropout and adverse effects. The total IES-R scores analysis of 41 patients post 1st infusion and crossover analysis of 29 patients’ post 2nd infusion were both significantly improved with ketamine compared with midazolam infusions (mean difference, 8.6 [95% CI, 0.94–16.2]; P = .03) and (mean difference, 12.7 [95% CI, 2.5–22.8]; P = .02), respectively.

Feder et al more recent study in 2021 randomly assigned 30 patients who received ketamine or midazolam infusions [26]. One patient was withdrawn from the study per protocol due to worsening PTSD symptoms after the second infusion. All included patients were also previously diagnosed with comorbid conditions (ex. MDD, GAD, OCD, and panic disorder). Total CAPS-5 scores between the ketamine and midazolam treatment groups were not significant at baseline (estimated difference = 0.87, SE = 3.93, P = 0.83). However, at week 1 and week 2, total CAPS-5 scores of the ketamine group were significantly lower compared to the midazolam group (ketamine group week 1: estimated difference = 8.80, SE = 3.93, P = 0.030, at week 2: estimated difference = 11.88, SE = 3.96, P = 0.004); (midazolam group week 1: effect size d = 0.85, 95% CI = 0.10, 1.59; at week 2: d = 1.13, 95% CI = 0.36, 1.91).

Pradhan et al 2017 randomly assigned 10 patients to receive ketamine or normal saline infusions with TIMBER psychotherapy (TIMBER-K vs TIMBER-P, respectively) [10]. All included patients were diagnosed with PTSD and comorbid depression. There were no significant differences in the baseline CAPS scores between the two arms; average ± SD values were 92.60 ± 5.13 (TIMBER-K) and 84.20 ± 8.73 (TIMBER-P), P = 0.101. All 10 patients obtained significant remission of PTSD symptoms with total CAPS scores of 88.40 ± 8.07 at baseline vs. 20.60 ± 7.53 at 24 hours post-infusion (P < 0.001). There were no significant differences in response between the two groups at 24 hours post-infusion with total CAPS scores of 17.80 ± 5.21 (TIMBER-K) vs 23.40 ± 8.99 (TIMBER-P) (P = 0.263). However, the TIMBER-K group had a more robust and sustained response (33 ± 22.98 days) as compared to those in the TIMBER-P group (25 ± 16.8 days), but this difference was not significant (P = 0.545).

Pradhan et al 2018 randomly assigned 20 patients to receive ketamine or normal saline infusions with TIMBER psychotherapy (TIMBER-K vs TIMBER-P, respectively) [11]. All included patients were diagnosed with PTSD and comorbid depression. There were no significant differences in the baseline PCL scores between the two arms: average ± SD values were 75.70 ± 5.81 (TIMBER-K) and 70.40 ± 7.74 (TIMBER-P), P = 0.0928. All 20 patients obtained significant remission of PTSD symptoms at 24 hours post-infusion with > 60% reduction (P < 0.0001) in both the PCL and CAPS scores. There were no significant differences in response between the two groups at 24 hours (ketamine vs normal saline). A difference was noted with the duration of sustained effect between the two groups. The TIMBER-K arm had a significantly greater sustained response than the TIMBER-P arm (34.44 ± 19.12 days vs 16.50 ± 11.39 days, P = 0.022, respectively).

Dadabayev et al 2020 (27 randomly assigned 41 patients to receive ketamine or ketorolac infusions [27]. Two patients were excluded from analysis due to unrelated medical illness and loss to follow-up. Nineteen included patients had comorbid chronic pain (CP) and PTSD, and the following 20 patients had a chronic pain diagnosis only. Total IES-R scores for the comorbid (CP + PTSD) group (n = 19) in both ketamine and ketorolac treatment arms had significantly decreased PTSD symptomology from baseline to seven days post-infusion (F(1,52) = 9.35, P < 0.01).

Interestingly, there was no significant PTSD symptom reduction from one day to seven day post infusion in the either comorbid arm (t(31.75) = 0.92, P = 0.37). Nor was there a significant reduction in the patients who were diagnosed with chronic pain only (P > 0.05).

Relapse:

Three RCTs investigated PTSD symptomology relapse [10, 11, 26]. Feder et al 2021reported a median time for PTSD symptomology relapse after 6 ketamine infusions was at 27.5 days [26]. Two patients remained in remission by their last assessments, which occurred 50 and 102 days after their primary outcome assessment, respectively [26]. The sustained response of the ketamine infusion with TIMBER psychotherapy group lasted for 33 ± 22.98 days [10] and 34.44 ± 19.12 days [11]. The sustained response of the ketamine infusion with TIMBER was twice as long compared to TIMBER therapy alone and 5x longer than the ketamine therapy alone [11].

Side effects:

Overall, no significant psychotic, manic, or suicidal symptoms were observed [10, 11, 17, 26, 27]. The most common side effect identified was dissociative symptoms [17, 26, 27]. Though common, dissociative symptoms were transient, peaking at 40 minutes and resolved by 120 minutes post ketamine infusion. One patient dropped out after the second ketamine infusion due to discomfort with dissociative effects [17] and one patient was withdrawn due to worsening PTSD symptoms after their second ketamine infusion [26]. Other reported side effects in the first 24 hours post ketamine infusions were blurred vision, dry mouth, restlessness, nausea/vomiting, headaches, and dizziness. Of the five patients with elevated blood pressure during ketamine infusions, four patients required treatment with β-blockers (these patients had blood pressures of systolic > 180 mm Hg and/or diastolic blood pressure > 100 mm Hg) [11, 17, 26, 27]. One study administered 4 mg IV ondansetron to all patients to reduce the development of nausea and vomiting [27].

A. Cohort Studies

Demographics:

For three cohort studies, there were 11 females and 24 males with a mean age of patients ranging from 25 to 66 years (Table 4) [28, 29, 31]. Majority of the patients had a prior history of combat, physical and sexual trauma (Table 5). The final cohort study consists of 30 US military veterans’ patients diagnosed with combat related PTSD [30].

Diagnostic Criteria:

The baseline diagnostic criteria for PTSD were consistent between four cohort studies [28–31]. All included patients had a current diagnosis of PTSD for at least 6 months with partial or lack of response to concomitant psychotropic medications and/or CBT trials. Diagnosis of PTSD was assessed using the DMS - V criteria [28–31]. Albott et al 2018 allowed patients to continue stable doses of psychotropic medications prior to randomization and throughout the study [28]. Notable exclusion criteria included unstable medical or non-psychiatric central nervous system conditions, moderate to severe traumatic brain injury, active substance use disorder in the past 6 months, lifetime history of DMS - V defined psychosis or Bipolar 1 or 2 disorder, or active suicidal ideation [28, 31].

Intervention:

Interventions ranged from single continuous ketamine infusion to six infusions. Only two cohort studies combined psychotherapy with ketamine pharmacotherapy [29, 31]. For details, please refer to Table 4.

Cohort Efficacy Results:

There were four cohort studies that reported a rapid and significant reduction in PTSD severity following ketamine infusions [28–31].

Albott et al 2018 reported on 15 patients who completed all 6 ketamine infusions. The included patients were all diagnosed with PTSD and comorbid depression [28]. There was a significant reduction in total CAPS-5 scores in 80% of the patients after completion of the 6 ketamine infusions (P < .0005).

Ross et al 2019 reported on 30 patients who completed all 6 ketamine infusions [30]. The included patients were all diagnosed with combat related PTSD and comorbid depression. There was a significant reduction in PCL-5 scores after completion of the 6 ketamine infusions, from an average score of 56.2 to 31.3, a 44% reduction, with a Cohen’s d effect size of 1.42 (P < .001).

Keizer et al 2020 reported on 11 patients who completed the full 96-hour ketamine infusion with a psychotherapy course [29]. The included patients were all diagnosed with PTSD and comorbid neuropathic pain. There was a significant reduction (> 35%) in pre-post PCL-5 scores in 65% of patients. A paired-samples t test showed a significant decrease (p = 0.003) in PCL-5 scores (pre-treatment mean 55.33, SD = 11.52 to post-treatment mean 27.11, SD = 12.36) 95% CI (13.11, 43.33), Cohen’s d = 1.44.

Shiroma et al 2020 reported on 9 patients who completed all 3 ketamine infusions and 10 exposure therapy sessions [31]. The included patients were veterans with diagnosed chronic and at least moderate PTSD. There was a significant reduction in pre-post CAP-5 scores (P = 0.001, -15.25 [95% CI, 7.27–23.23], d = 1.21).

Relapse:

Only one cohort study investigated PTSD symptom relapse. Median time for PTSD symptomology relapse was at 41 days. 14 days after the final 6th ketamine infusion, 80% of patients were in remission. Forty percent of patients remained in remission at the completion of the complete 56-day follow-up period [28].

Side effects:

The majority of side effects were seen during and immediately after the completion of the ketamine infusions. Dissociative symptoms [28], visual perception alterations (ranging from benign sensory disturbance to hallucinations [29], and increase in known PTSD symptoms [30] returned to baseline by the end of the recovery period. Seven patients required treatment with β-blockers for elevated blood pressure during ketamine infusions (systolic > 180 mm Hg and/or diastolic blood pressure > 100 mm Hg) [28, 31].

We analyzed each included study for their control and test group baseline and post interventions outcome score based on their respective PTSD scale. There was no significant difference at baseline between the ketamine and control groups in the RCTs (standardized mean difference: 0.10, 95% confidence interval -0.44 – 0.65, P = 0.34) (Figure 2).

Meta-analysis of all studies revealed that ketamine infusion reduced PTSD symptom severity substantially (ketamine standardized mean difference pre-to-post: 3.07, 95% confidence interval 1.54 – 4.60, P<0.01) (Figure 3). There were significant differences between the ketamine groups vs control groups of the RCTs at the follow up period (moderate standardized mean difference: -0.58, 95% confidence interval -0.95 – -0.21, P = 0.002) (Figure 4).

There were significant differences between the pre-post control groups of the RCTs (standardized mean difference pre-to-post: 2.85, 95% confidence interval 0.50 – 5.20, P<0.01) (Figure 5). We postulate this significant difference between the pre/post control groups is due to the beneficial effects of the novel TIMBER psychotherapy.

Principal Findings:

Our study adds to the existing literature by providing a meta-analysis of the specific relationship between ketamine infusions and its effect on PTSD symptomology. In all included studies, ketamine infusions were shown to improve PTSD symptom severity [10, 11, 17, 26-31]. Ketamine assisted psychotherapy not only extended ketamine’s effectiveness but also prolonged remission from PTSD. The statistically significant associations that were reported occurred in a diverse age range of patients with varying types of past trauma.

Comparable Literature:

There have been promising results of ketamine infusion for treatment resistant major depression with its recent FDA approval in 2019 [16]. Unfortunately, the current state of PTSD therapy falls severely short of any adequate advances. Krystal et al. 2017 advocate for further PTSD therapy research as it should be a national mental health priority [13].

Glutamate dysfunctions in CNS have been the predominant neurobiological hypothesis for the perpetuation of symptoms in chronic PTSD and NMDA receptor activation plays a role in over-consolidation of intrusive traumatic memories [18]. Ketamine administration is a known receptor NMDA receptor antagonist that induces and enhances neuroplasticity and modulates glutamatergic transmission which can reverse the stress-induced neuronal changes [32].

A recent meta-analysis investigated ketamine’s effect on PTSD for military soldiers [33]. Du et al. determined ketamine had no effect in reducing PTSD incidence for soldiers on the battlefield. Interestingly, it was shown that ketamine was not only ineffective in treating early PTSD but also led to exacerbation of the PTSD [33]. However, in their longitudinal study analysis, ketamine was shown to be effective in treating chronic PTSD [33]. It is possible that there is an inadequate consolidation of traumatic memories in acute PTSD whereby ketamine cannot induce its modulatory effects on early stress induced neurons.

Our study supports Du et al.’s results [33] and builds on the importance of including psychotherapy with pharmacological treatment for PTSD. Psychotherapy is a first-line treatment for PTSD, though its effects are short-lived. Hoge et al. showed the effectiveness of mindfulness meditation and yoga in changing brain chemistry in patients with general anxiety disorder [34]. These practices were seen to reduce concentrations of GABA, adrenocorticotropic hormone and pro-inflammatory cytokines which in turn led to a reduction in mental stress [34].

The combination of ketamine-assisted psychotherapy (KAT) has shown promising results in various psychiatric conditions. Krupitsky et al. highlighted the significant abstinence effect of multiple KAT sessions for patients with heroin dependence [35]. At the end of one year, the rate of abstinence in the multiple KAT session group was twice as high as the single KAT session group [35].

Four of the included studies investigated KAT for PTSD treatment [10, 11, 29, 31]. Both of Pradhan et al KAT methodology included one infusion (ketamine or normal saline) with 12 sessions of TIMBER psychotherapy [10, 11]. Significant decreases were noted in PTSD symptoms in both study arms at the 24-hour time point suggesting that the TIMBER protocol contributed to the clinical change in both groups [10, 11]. Bolstering their results, they noted that TIMBER psychotherapy alone produced a significant reduction (~10%) in basal plasma concentrations of D-serine at the 40-minute time point [11]. D-serine was identified as a NMDA receptor co-agonist that not only induces long term potentiation and NMDA-induced neurotoxicity but also acquisition and extinction of fear memory in animals and patients with PTSD [36, 37].

Keizer et al.’s KAT methodology included an incremental increase of ketamine (until a final dose of 11 – 15 μg/kg/min was achieved) over ~96 hours with 90 minutes of psychotherapy [29]. Though patients included in the study participated in psychotherapy in the year prior, the 5 days of therapy achieved optimistic breakthroughs of patients' internalizing of their traumatic memories. 90% of patients were more dedicated to psychotherapy post-infusion [29]. Patients were able to unmask previous trauma and enhance interpersonal relationships. For combat-specific PTSD, patients were able to configure their therapy to underlying pre-combat sexual and/or physical abuse and subsequent life experiences and consequences [29]. Shiroma et al’s KAT methodology included multiple ketamine infusions(3), which further highlighted the synergistic effect of ketamine with KAT [31].

Ketamine is utilized due to its fast-acting effects (~40 minutes) but its insufficient lasting effects of 1-2 weeks undermines its utility [15, 17]. Though only 42% (3/7) of included studies reported long-term remission data, it is an effective measure to determine which methodology obtains long-lasting relief [11, 26, 28]. Pradhan et al 2018 unique KAT protocol (single ketamine infusion) had noted a sustained response for a median PTSD symptomology relapse time that was twice as long compared to TIMBER therapy alone and 5x longer than the ketamine therapy alone [11].

Our study highlights the integral union of psychotherapy with ketamine therapy for PTSD. Psychotherapy not only enhances ketamine’s effect but also prolongs PTSD symptom remission. A single ketamine infusion with appropriate psychotherapy is shown to be at least as effective, if not better, in prolonging remission times. These promising results can help shape future research on limiting the required dosage/infusion number for PTSD therapy which in turn lowers the risk of tolerance and side effects (notably dissociative symptoms [17, 26, 28-30] and elevated blood pressure [11, 17, 26, 28]).

Limitations:

All studies were limited with a small sample size. The largest[17] and smallest [29] sample size were 41 and 11 patients, respectively. Generalizability of the results were a major limitation due to the exclusion of patients with comorbid psychotic, bipolar, active suicidal or homicidal ideation on presentation current alcohol or substance use disorders in order to protect against worsening of psychotic symptoms or abuse potential [17, 26, 27]. One study did not maintain per protocol analysis since 14% of patients did not undergo a second ketamine infusion due to the sustained reduction in PTSD symptom levels 2 weeks after ketamine infusion and a modified intention to treat analysis was undertaken [17]. The design of open-label studies with no placebo group limits contextualization of results due to lack of control group results and blinding. The cohort study with the largest sample size of n = 30 did not delineate their patient demographics in detail [30]. Although Albott et al 2018 and Shiroma et al appropriately described their statistical analysis, Keizer et al and Ross et al did not describe their statistical analysis to the readers [28-31]. Since each study obtained its PTSD symptom severity through various scales (CAPS-5, PCL-5, and IES-R), standardization with the gold standard Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) should be used for future protocols. Further knowledge of how individual variables in each scale changed over the course of the ketamine infusions would give insight into which parts of the patient’s recurrent trauma is being affected.

This meta-analysis analyzes the therapeutic relationship between ketamine and chronic PTSD across nine studies. In summary, the results support ketamine infusions as an effective treatment modality in alleviating PTSD symptoms as evidenced by the standardized mean difference pre-to-post: 3.07, 95% confidence interval 1.54 – 4.60, P<0.01. Ketamine assisted psychotherapy is shown to enhance ketamine effect with the longest sustained response with only 1 ketamine infusion 33 ± 22.98 days[10] and 34.44 ± 19.12 days[11]. Limitations included small sample sizes in included studies and lack of standardization of PTSD scales. Future studies should include more longitudinal data to ascertain remission status based on number of ketamine infusions and psychotherapy sessions completed. In light of the ongoing COVID-19 pandemic and its unforeseen consequences on PTSD [38, 39], further research is urgently needed to make strides in a more effective and long-lasting PTSD treatment.

PTSD: Post-traumatic stress disorder, NMDA: N-methyl-D-aspartate, RCT: Randomized Control Trial, TIMBER: trauma interventions using mindfulness-based extinction and reconsolidation of trauma memories, CBT: Cognitive behavioral therapy, SSRI: selective serotonin reuptake inhibitors, FDA: Food and Drug Administration, KAT: ketamine-assisted psychotherapy, PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-analyses

Ethics approval and consent to participate: This is a Meta-Analysis study. The Cooper Research Ethics Committee has confirmed that no ethical approval is required.

Consent for publication: Not applicable

Availability of data and materials: All data generated or analyzed during this study are included in this published article

Competing interests: The authors declare that they have no competing interests.

Funding: Not applicable

Authors' contributions:

All authors contributed to the study conception and design. Material preparation was completed by C.M, B.P, L.M, B.S, H.W.K, and N.v.H. Data collection was completed by B.S. Data analysis was completed by C.M, B.P, K.H, H.W.K, and N.v.H. The first draft of the manuscript was written by C.M and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Acknowledgements: Not applicable

Goldstein RB, Smith SM, Chou SP, et al. The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Soc Psychiatry Psychiatr Epidemiol. 2016;51(8):1137-1148. https://doi.org/10.1007/s00127-016-1208-5.
Merikangas KR, He JP, Burstein M, et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication--Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry. 2010;49(10):980-989. https://doi.org/10.1016/j.jaac.2010.05.017.
Kessler RC, Aguilar-Gaxiola S, Alonso J, et al. Trauma and PTSD in the WHO World Mental Health Surveys. Eur J Psychotraumatol. 2017;8(sup5):1353383. Published 2017 Oct 27. https://doi.org/10.1080/20008198.2017.1353383.
Hoge CW, Auchterlonie JL, Milliken CS. Mental health problems, use of mental health services, and attrition from military service after returning from deployment to Iraq or Afghanistan. JAMA. 2006;295(9):1023-1032. https://doi.org/10.1001/jama.295.9.1023.
Koenen KC, Ratanatharathorn A, Ng L, et al. Posttraumatic stress disorder in the World Mental Health Surveys. Psychol Med. 2017;47(13):2260-2274. https://doi.org/10.1017/S0033291717000708.
Alexander W. Pharmacotherapy for Post-traumatic Stress Disorder In Combat Veterans: Focus on Antidepressants and Atypical Antipsychotic Agents. P T. 2012;37(1):32-38.
Berger W, Mendlowicz MV, Marques-Portella C, et al. Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(2):169-180. https://doi.org/10.1016/j.pnpbp.2008.12.004.
Zohar J, Amital D, Miodownik C, et al. Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. J Clin Psychopharmacol. 2002;22(2):190-195. https://doi.org/10.1097/00004714-200204000-00013.
Asnis GM, Kohn SR, Henderson M, Brown NL. SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations. Drugs. 2004;64(4):383-404. https://doi.org/10.2165/00003495-200464040-00004.
Pradhan BK, Wainer IW, Moaddel R, et al. Trauma Interventions using Mindfulness Based Extinction and Reconsolidation (TIMBER) psychotherapy prolong the therapeutic effects of single ket- amine infusion on post-traumatic stress disorder and comorbid depression: a pilot randomized, placebo-controlled, cross-over clinical trial. Asia Pac J Clin Trials Nerv Syst Dis 2017;2(3):80-90.
Pradhan B, Mitrev L, Moaddell R, Wainer IW. d-Serine is a potential biomarker for clinical response in treatment of post-traumatic stress disorder using (R,S)-ketamine infusion and TIMBER psychotherapy: A pilot study. Biochim Biophys Acta Proteins Proteom. 2018;1866(7):831-839. https://doi.org/10.1016/j.bbapap.2018.03.006.
Steenkamp MM, Litz BT, Hoge CW, Marmar CR. Psychotherapy for Military-Related PTSD: A Review of Randomized Clinical Trials. JAMA. 2015;314(5):489-500. https://doi.org/10.1001/jama.2015.8370.
Krystal JH, Davis LL, Neylan TC, et al. It Is Time to Address the Crisis in the Pharmacotherapy of Posttraumatic Stress Disorder: A Consensus Statement of the PTSD Psychopharmacology Working Group [published correction appears in Biol Psychiatry. 2018 Feb 1;83(3):296]. Biol Psychiatry. 2017;82(7):e51-e59. https://doi.org/10.1016/j.biopsych.2017.03.007.
Singh JB, Fedgchin M, Daly EJ, et al. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. Am J Psychiatry. 2016;173(8):816-826. https://doi.org/10.1176/appi.ajp.2016.16010037.
Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134-1142. https://doi.org/10.1176/appi.ajp.2013.13030392.
FDA approves new nasal spray medication for treatment-resistant depression; available only at a Certified Doctor's Office or clinic. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified. Published March 5, 2019. Accessed December 28, 2022.
Feder A, Parides MK, Murrough JW, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014;71(6):681-688. https://doi.org/10.1001/jamapsychiatry.2014.62.
Liriano F, Hatten C, Schwartz TL. Ketamine as treatment for post-traumatic stress disorder: a review. Drugs Context. 2019;8:212305. Published 2019 Apr 8. https://doi.org/10.7573/dic.212305.
Krystal JH, Abdallah CG, Averill LA, et al. Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic. Curr Psychiatry Rep. 2017;19(10):74. Published 2017 Aug 26. https://doi.org/10.1007/s11920-017-0829-z.
McGhee LL, Maani CV, Garza TH, Gaylord KM, Black IH. The correlation between ketamine and posttraumatic stress disorder in burned service members. J Trauma. 2008;64(2 Suppl):S195-S198. https://doi.org/10.1097/TA.0b013e318160ba1d.
Krupitsky EM, Burakov AM, Dunaevsky IV, Romanova TN, Slavina TY, Grinenko AY. Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs. 2007;39(1):13-19. https://doi.org/10.1080/02791072.2007.10399860.
Feder A, Rutter SB, Schiller D, Charney DS. The emergence of ketamine as a novel treatment for posttraumatic stress disorder. Adv Pharmacol. 2020;89:261-286. https://doi.org/10.1016/bs.apha.2020.05.004
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. Published 2021 Mar 29. https://doi.org/10.1136/bmj.n71.
Noud van Helmond, Basant Pradhan, Ludmil Mitrev, Michael Sabia, Benjamin Saracco, Krystal Hunter, Kingsuk Ganguly, Jasjit Sehdev, Cyrus Movdawalla. Is ketamine infusion an effective treatment for post-traumatic stress disorder?. PROSPERO 2020 CRD42020184237.
National Heart, Lung, and Blood Institute. (2019). Study Quality Assessment Tools [https://www. nhlbi. nih. gov/health-topics/study-quality-assessment-tools].
Feder A, Costi S, Rutter SB, et al. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. Am J Psychiatry. 2021;178(2):193-202. https://doi.org/10.1176/appi.ajp.2020.20050596.
Dadabayev AR, Joshi SA, Reda MH, et al. Low Dose Ketamine Infusion for Comorbid Posttraumatic Stress Disorder and Chronic Pain: A Randomized Double-Blind Clinical Trial. Chronic Stress (Thousand Oaks). 2020;4:2470547020981670. Published 2020 Dec 22. https://doi.org/10.1177/2470547020981670.
Albott CS, Lim KO, Forbes MK, et al. Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression. J Clin Psychiatry. 2018;79(3):17m11634. https://doi.org/10.4088/JCP.17m11634.
Keizer BM, Roache JD, Jones JR, Kalpinski RJ, Porcerelli JH, Krystal JH. Continuous Ketamine Infusion for Pain as an Opportunity for Psychotherapy for PTSD: A Case Series of Ketamine-Enhanced Psychotherapy for PTSD and Pain (KEP-P2). Psychother Psychosom. 2020;89(5):326-329. https://doi.org/10.1159/000507095.
Ross C, Jain R, Bonnett CJ, Wolfson P. High-dose ketamine infusion for the treatment of posttraumatic stress disorder in combat veterans. Ann Clin Psychiatry. 2019;31(4):271-279.
Shiroma PR, Thuras P, Wels J, Erbes C, Kehle-Forbes S, Polusny M. A Proof-of-Concept Study of Subanesthetic Intravenous Ketamine Combined With Prolonged Exposure Therapy Among Veterans With Posttraumatic Stress Disorder. J Clin Psychiatry. 2020;81(6):20l13406. Published 2020 Nov 10. https://doi.org/10.4088/JCP.20l13406.
Greenway KT, Garel N, Jerome L, Feduccia AA. Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments. Expert Rev Clin Pharmacol. 2020;13(6):655-670. https://doi.org/10.1080/17512433.2020.1772054.
Du R, Han R, Niu K, et al. The Multivariate Effect of Ketamine on PTSD: Systematic Review and Meta-Analysis. Front Psychiatry. 2022;13:813103. Published 2022 Mar 9. https://doi.org/10.3389/fpsyt.2022.813103
Hoge EA, Bui E, Palitz SA, et al. The effect of mindfulness meditation training on biological acute stress responses in generalized anxiety disorder. Psychiatry Res. 2018;262:328-332. https://doi.org/10.1016/j.psychres.2017.01.006.
Krupitsky EM, Burakov AM, Dunaevsky IV, Romanova TN, Slavina TY, Grinenko AY. Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs. 2007;39(1):13-19. https://doi.org/10.1080/02791072.2007.10399860.
Wolosker H, Dumin E, Balan L, Foltyn VN. D-amino acids in the brain: D-serine in neurotransmission and neurodegeneration. FEBS J. 2008;275(14):3514-3526. https://doi.org/10.1111/j.1742-4658.2008.06515.x.
Balu DT, Presti KT, Huang CCY, et al. Serine Racemase and D-serine in the Amygdala Are Dynamically Involved in Fear Learning. Biol Psychiatry. 2018;83(3):273-283. https://doi.org/10.1016/j.biopsych.2017.08.012.
Walton M, Murray E, Christian MD. Mental health care for medical staff and affiliated healthcare workers during the COVID-19 pandemic. Eur Heart J Acute Cardiovasc Care. 2020;9(3):241-247. https://doi.org/10.1177/2048872620922795.
Forte G, Favieri F, Tambelli R, Casagrande M. COVID-19 Pandemic in the Italian Population: Validation of a Post-Traumatic Stress Disorder Questionnaire and Prevalence of PTSD Symptomatology. Int J Environ Res Public Health. 2020;17(11):4151. Published 2020 Jun 10. https://doi.org/10.3390/ijerph17114151.

Table 2 and 3 are available in the Supplementary Files section.

No competing interests reported.

Is Ketamine Infusion an Effective Treatment for Post-Traumatic Stress Disorder? A Meta-Analysis

Status:

Version 1

Abstract

Figures

I. Introduction

II. Methods

III. Literature Review Results

IV. Meta-Analysis of Results of RCTs and Cohort Studies

V. Discussion

VI. Conclusion and Directions for Future Research

Abbreviations

Declarations

References

Tables

Additional Declarations

Supplementary Files

Status:

Version 1